Aspo Plc
Aspo Plc - Managers' Transactions – Mikko Pasanen
Aspo Plc - Managers' Transactions – Mikko Pasanen
Aspo Plc Managers’ transactions November 7, 2025, at 13.15 EET
Aspo Plc - Managers' Transactions – Mikko Pasanen
___________________________________________
Name: Mikko Pasanen
Position: Other senior manager
Issuer: Aspo Oyj
LEI: 7437000TB0GHDHLPX677
Notification type: INITIAL NOTIFICATION
Reference number: 129614/7/6
____________________________________________
Transaction date: 2025-11-05
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009008072
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 129 Unit price: 6.56 EUR
(2): Volume: 93 Unit price: 6.56 EUR
(3): Volume: 101 Unit price: 6.56 EUR
(4): Volume: 189 Unit price: 6.6 EUR
(5): Volume: 209 Unit price: 6.6 EUR
(6): Volume: 150 Unit price: 6.6 EUR
(7): Volume: 2 Unit price: 6.62 EUR
(8): Volume: 217 Unit price: 6.66 EUR
(9): Volume: 800 Unit price: 6.66 EUR
(10): Volume: 22 Unit price: 6.66 EUR
(11): Volume: 5 Unit price: 6.66 EUR
(12): Volume: 134 Unit price: 6.66 EUR
(13): Volume: 150 Unit price: 6.66 EUR
(14): Volume: 500 Unit price: 6.66 EUR
(15): Volume: 349 Unit price: 6.66 EUR
(16): Volume: 500 Unit price: 6.64 EUR
(17): Volume: 229 Unit price: 6.64 EUR
(18): Volume: 4 Unit price: 6.64 EUR
(19): Volume: 116 Unit price: 6.68 EUR
(20): Volume: 456 Unit price: 6.68 EUR
(21): Volume: 8 Unit price: 6.68 EUR
(22): Volume: 101 Unit price: 6.68 EUR
(23): Volume: 131 Unit price: 6.68 EUR
(24): Volume: 67 Unit price: 6.66 EUR
(25): Volume: 300 Unit price: 6.68 EUR
(26): Volume: 33 Unit price: 6.68 EUR
(27): Volume: 200 Unit price: 6.68 EUR
(28): Volume: 400 Unit price: 6.68 EUR
(29): Volume: 172 Unit price: 6.68 EUR
(30): Volume: 1000 Unit price: 6.7 EUR
(31): Volume: 1000 Unit price: 6.68 EUR
(32): Volume: 260 Unit price: 6.68 EUR
(33): Volume: 101 Unit price: 6.68 EUR
Aggregated transactions (33):
Volume: 8128 Volume weighted average price: 6.66315 EUR
____________________________________________
Transaction date: 2025-11-06
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009008072
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 750 Unit price: 6.82 EUR
(2): Volume: 221 Unit price: 6.78 EUR
(3): Volume: 63 Unit price: 6.78 EUR
(4): Volume: 300 Unit price: 6.78 EUR
(5): Volume: 11 Unit price: 6.78 EUR
(6): Volume: 58 Unit price: 6.8 EUR
(7): Volume: 40 Unit price: 6.8 EUR
(8): Volume: 60 Unit price: 6.8 EUR
(9): Volume: 14 Unit price: 6.8 EUR
(10): Volume: 5 Unit price: 6.8 EUR
(11): Volume: 150 Unit price: 6.8 EUR
(12): Volume: 84 Unit price: 6.8 EUR
(13): Volume: 89 Unit price: 6.8 EUR
(14): Volume: 403 Unit price: 6.86 EUR
Aggregated transactions (14):
Volume: 2248 Volume weighted average price: 6.81214 EUR
Aspo Plc
Erkka Repo
CFO
Distribution:
Nasdaq Helsinki
www.aspo.com
For more information, please contact: Erkka Repo, CFO, Aspo Plc, tel. +358 40 5827 971, erkka.repo@aspo.com
Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo’s businesses – ESL Shipping, Telko and Leipurin – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 800 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia.
Aspo is listed on Nasdaq Helsinki and is headquartered in Finland.
Aspo – Sustainable value creation
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Centessa Pharmaceuticals plc7.11.2025 14:00:00 CET | Press release
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Sanofi Winthrop Industrie7.11.2025 14:00:00 CET | Press release
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
PolTREG S.A.7.11.2025 14:00:00 CET | Press release
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
SKAKO A/S7.11.2025 13:34:43 CET | Pressemeddelelse
Trading report Q3 2025 SKAKO A/S
Fast Ejendom Danmark7.11.2025 13:34:01 CET | Pressemeddelelse
Aktietilbagekøbsprogram
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom